Analyst Expects Biomarin Pharmaceutical Inc. (NASDAQ: BMRN) To Make Big Moves

After Hours

There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Stocks Info

As a NASDAQ listed company, BMRN falls under the Healthcare sector while operating within the Biotechnology industry segment. The current market capitalization of Biomarin Pharmaceutical Inc. is $15.70B. A total of 1.44 million shares were traded on the day, compared to an average of 2.66M shares.

In the most recent transaction, Mueller Brian sold 5,000 shares of BMRN for 75.19 per share on May 30 ’24. After the transaction, the EVP, Chief Financial Officer now owns 72,159 company shares. In a previous transaction on May 28 ’24, Davis George Eric sold 40,850 shares at 74.51 per share. BMRN shares that EVP, Chief Legal Officer owns now total 56,157.

Among the insiders who sold shares, BIENAIME JEAN JACQUES disposed of 20,000 shares on May 10 ’24 at a per-share price of $81.14. This resulted in the Director holding 474,994 shares of BMRN after the transaction. In another insider transaction, BIENAIME JEAN JACQUES sold 20,000 shares at $81.62 per share on May 09 ’24. Company shares held by the Director now total 474,994.

In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. In terms of 52-week highs and lows, BMRN has a high of $99.56 and a low of $73.68.

As of this writing, BMRN has an earnings estimate of $0.34 per share for the current quarter. EPS was calculated based on a consensus of 16.0 estimates, with a high estimate of $0.55 per share and a lower estimate of $0.17. The company reported an EPS of $0.29 in the last quarter

Balance Sheet Annually/Quarterly

The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. BMRN’s latest balance sheet shows that the firm has $1.01B in Cash & Short Term Investments as of fiscal 2021. There were $1.09B in debt and $546.50M in liabilities at the time. Its Book Value Per Share was $26.74, while its Total Shareholder’s Equity was $4.27B.

Analysts Opinion

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for BMRN is Buy with a score of 4.36.

Most Popular

Related Posts